French software firm Dassault Systèmes lowered its full-year revenue growth forecast to 4–6%, down from a previous estimate of 6–8%, after posting weaker-than-expected third-quarter results. The company cited slower performance in its Life Sciences and CENTRIC PLM divisions.
Quarterly revenue was flat at €1.46 billion ($1.7 billion), missing analyst expectations by about 3%, while operating profit came in at €440 million, roughly 2% below forecasts, according to LSEG data. Shares slipped as investors reacted to the guidance cut.
J.P. Morgan analysts described the results as “disappointing,” pointing to weaker Medidata growth and challenges in the transition to Centric PLM’s cloud-based software model. Despite near-term headwinds, CFO Rouven Bergmann said AI-driven tools are expected to contribute meaningfully to revenue from 2026, estimating between €50 million and €100 million in early gains that year.
Meanwhile, Medidata announced an expanded partnership with Sanofi to enhance clinical trials using its patient and data management platforms — part of Dassault’s broader effort to strengthen its Life Sciences software ecosystem.
